Acción CEL-SCI CORPORATION
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas CEL-SCI Corporation Nyse

Acciones

US1508375086

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Cel-Sci Appoints Robert Watson Board's Chair
CEL-SCI Appoints Robert Watson as Chairperson of the Board
CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board
CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell Microcap Value Index
CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index
CEL-SCI Corporation Presents Head & Neck Cancer Data At Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated with Multikine in the Target Population
CEL-SCI Presents Head and Neck Cancer Data at Iddst Annual Congress in Budapest, Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
CEL-SCI Corporation (von First Berlin Equity Research GmbH...
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
Cel-Sci: Fiscal Q2 Earnings Snapshot
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer
Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine
CEL-SCI Corporation Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción CVM
  4. Acción
  5. Noticias CEL-SCI Corporation
  6. Otros idiomas